Muscle Relaxants During Heart Rhythm Ablation Procedure for Safety
Tests whether muscle relaxants lessen muscle damage during a heart rhythm ablation procedure.
Plain-language title generated from the registry record
Registry title: The Potential Protective Effect of Using Muscle Relaxants During Electroporation Ablation (PFA)
Key facts
- Where
- Wroclaw, PolandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT06707532, who can take part
Where in Poland
- 4th Military Clinical Hospital with PolyclinicWroclaw, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- 4th Military Clinical Hospital with Polyclinic, Poland
- Trial code
- NCT06707532
- Record updated
- 27 November 2024
- Original description
The study aims to improve the safety of the electroporation ablation (PFA) procedure by using muscle relaxants to reduce skeletal muscle damage during the procedure. It will also assess myocardial damage to improve the procedure's quality and speed up recovery after the procedure.Read full original descriptionShow less
The Use of Muscle Relaxants During Electroporation Ablation (PFA) as a Potential Protective Factor Against Damage to Transverse Striated Muscle Tissue and the Heart
The study aims to improve the safety of the electroporation ablation (PFA) procedure by using muscle relaxants to reduce skeletal muscle damage during the procedure. It will also assess myocardial damage to improve the procedure's quality and speed up recovery after the procedure.
Inclusion: Patients with requirement for PFA ablation for cardiac indications and ability to provide informed consent for study participation.
Exclusion: Patients with allergies to the general anaesthetics used, genetic diseases of the neuromuscular plateau - e.g. Duchenne dystrophy, myasthenia gravis - and patients who do not gived informed consent to participate in the study will be excluded from the study.